المؤلفون: Higashi, Michiyo^Aff2, Tamada, Shugo^Aff2, Nagata, Kohji^Aff2, Goto, Masamichi^Aff2, Yonezawa, Suguru^Aff2

المساهمون: Hayat, M. A., editor^{Aff1, Aff1}

المصدر: Liver Cancer. 5:451-459

المؤلفون: Hurst, Helen C.

المساهمون: Conn, P. Michael, editor, Ethier, Stephen P., editor^Aff1

المصدر: Endocrine Oncology. :69-77

Degree: PhD

المؤلفون: Wärri, Anni M., Härkönen, Pirkko L.

المساهمون: Kellen, John A., editor^Aff1

المصدر: Tamoxifen : Beyond the Antiestrogen. :343-358

المؤلفون: Wärri, Anni M., Isola, Jorma J., Härkönen, Pirkko L.

المساهمون: Li, J. Jonathan, editor^{Aff1, Aff6}, Li, Sara Antonia, editor^{Aff2, Aff6}, Gustafsson, Jan-Åke, editor^Aff3, Nandi, Satyabrata, editor^Aff4, Sekely, Lea I., editor^{Aff5, Aff7}

المصدر: Hormonal Carcinogenesis II : Proceedings of the Second International Symposium. :418-423

Degree: Ph.D.
M.D., Ph.D.

المؤلفون: Rao, Ghanta N., Ney, Elizabeth, Herbert, Ronald A.

المصدر: Breast Cancer Research and Treatment. December 1999 58(3):239-252

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Luc Dirix, Jacques De Greve, Walter Jonat, Martina Uttenreuther-Fischer, Matthias W. Beckmann, Nadia Harbeck, Martin Schuler, Frank Fleischer, Jean-Luc Canon, Peter A. Fasching, Patrick Neven, Jochen Schütte, Ahmad Awada, Philipp Harter, Sven Wind, Marcus Schmidt, Martine Piccart, T. Besse-Hammer, Kurt Possinger, Nina Gottschalk

المساهمون: Laboratory for Medical and Molecular Oncology

المصدر: Breast Cancer Research and Treatment
Breast cancer research and treatment, 134 (3

مصطلحات موضوعية: Oncology, Cancer Research, Receptor, ErbB-2, Afatinib, Medizin, Phases of clinical research, EGFR TKI, Quinazolines -- administration & dosage -- adverse effects -- therapeutic use, Cohort Studies, tyrosine kinase inhibitors, cetuximab, Clinical endpoint, Tumor Markers, Biological -- metabolism, Neoplasm Metastasis, skin and connective tissue diseases, Triple-negative breast cancer, estrogen-receptor, Aged, 80 and over, basal-like phenotype, Middle Aged, Metastatic breast cancer, Clinical Trial, Treatment Outcome, Response Evaluation Criteria in Solid Tumors, ADVANCED SOLID TUMORS, Cohort, Female, medicine.drug, Receptor, erbB-2 -- deficiency -- metabolism, Adult, medicine.medical_specialty, EGFR, Antineoplastic Agents, Breast Neoplasms, Breast Neoplasms -- drug therapy -- metabolism -- mortality -- pathology, Breast cancer, ERBB2 expression, Internal medicine, HER2, medicine, Biomarkers, Tumor, Humans, Protein Kinase Inhibitors, Aged, business.industry, Antineoplastic Agents -- adverse effects -- pharmacology -- therapeutic use, medicine.disease, Survival Analysis, HER2-negative breast cancer, Cancérologie, lung cancer, Quinazolines, Protein Kinase Inhibitors -- adverse effects -- pharmacology -- therapeutic use, business, GROWTH-FACTOR RECEPTOR

وصف الملف: 1 full-text file(s): application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0024de3117e9de521402b04945348a27
https://pubmed.ncbi.nlm.nih.gov/22763464

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.